|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
| We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/07/19 Sarepta Therapeutics, Inc. 10-Q 6/30/19 80:11M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Q2 2019 10-Q HTML 1.35M
2: EX-10.1 Material Contract HTML 43K
3: EX-10.2 Material Contract HTML 29K
4: EX-10.3 Material Contract HTML 30K
5: EX-10.4 Material Contract HTML 33K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 29K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 29K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
16: R1 Document and Entity Information HTML 68K
17: R2 Condensed Consolidated Balance Sheets HTML 109K
18: R3 Condensed Consolidated Balance Sheets HTML 48K
(Parenthetical)
19: R4 Condensed Consolidated Statements of Operations HTML 88K
and Comprehensive Loss
20: R5 Condensed Consolidated Statements of Stockholders' HTML 88K
Equity
21: R6 Condensed Consolidated Statements of Cash Flows HTML 143K
22: R7 Organization and Nature of Business HTML 29K
23: R8 Summary of Significant Accounting Policies and HTML 50K
Recent Accounting Pronouncements
24: R9 License and Collaboration Agreements HTML 62K
25: R10 Fair Value Measurements HTML 181K
26: R11 Cash, Cash Equivalents and Marketable Securities HTML 185K
27: R12 Accounts Receivable and Reserves for Product Sales HTML 99K
28: R13 Inventory HTML 45K
29: R14 Other Current Assets and Other Non-Current Assets HTML 98K
30: R15 Accrued Expenses HTML 75K
31: R16 Stock-Based Compensation HTML 154K
32: R17 Other Expense, Net HTML 69K
33: R18 Leases HTML 111K
34: R19 Net Loss Per Share HTML 69K
35: R20 Commitments and Contingencies HTML 50K
36: R21 Summary of Significant Accounting Policies and HTML 59K
Recent Accounting Pronouncements (Policies)
37: R22 License and Collaboration Agreements (Tables) HTML 53K
38: R23 Fair Value Measurements (Tables) HTML 175K
39: R24 Cash, Cash Equivalents and Marketable Securities HTML 185K
(Tables)
40: R25 Accounts Receivable and Reserves for Product Sales HTML 102K
(Tables)
41: R26 Inventory (Tables) HTML 46K
42: R27 Other Current Assets and Other Non-Current Assets HTML 100K
(Tables)
43: R28 Accrued Expenses (Tables) HTML 74K
44: R29 Stock-Based Compensation (Tables) HTML 159K
45: R30 Other Expense, Net (Tables) HTML 68K
46: R31 Leases (Tables) HTML 111K
47: R32 Net Loss Per Share (Tables) HTML 68K
48: R33 Commitments and Contingencies (Tables) HTML 41K
49: R34 Organization and Nature of Business - Additional HTML 38K
Information (Detail)
50: R35 Summary of Significant Accounting Policies and HTML 61K
Recent Accounting Pronouncements - Additional
Information (Detail)
51: R36 License and Collaboration Agreements - Additional HTML 56K
Information (Detail)
52: R37 License and Collaboration Agreements - Schedule of HTML 55K
Total Consideration of Business Acquisition
(Details)
53: R38 Assets and Liabilities Measured and Carried at HTML 60K
Fair Value (Detail)
54: R39 Summary of Company Financial Assets with HTML 32K
Maturities of Less Than 90 Days Included in Cash
Equivalents (Detail)
55: R40 Cash, Cash Equivalents and Marketable Securities - HTML 25K
Additional Information (Detail)
56: R41 Summary of Company Cash, Cash Equivalents and HTML 70K
Short-term Investments (Detail)
57: R42 Summary of Components of Accounts Receivable HTML 31K
(Detail)
58: R43 Summary of Change in Reserves for Discounts and HTML 42K
Allowances (Detail)
59: R44 Summary of Total Reserves Included in Consolidated HTML 29K
Balance Sheets (Detail)
60: R45 Summary of Components of Inventory (Detail) HTML 36K
61: R46 Summary of Other Current Assets (Detail) HTML 45K
62: R47 Summary of Other Non-current Assets (Detail) HTML 39K
63: R48 Summary of Accrued Expenses (Detail) HTML 54K
64: R49 Summary of Stock Awards Granted (Detail) HTML 41K
65: R50 Stock Based Compensation - Additional Information HTML 27K
(Detail)
66: R51 Summary of Stock-Based Compensation Expense by HTML 33K
Function Included within Condensed Consolidated
Statements of Operations and Comprehensive Loss
(Detail)
67: R52 Summary of Stock-Based Compensation Expense by HTML 35K
Grant Type Included within Condensed Consolidated
Statements of Operations and Comprehensive Loss
(Detail)
68: R53 Summary of Other Expense, Net (Detail) HTML 37K
69: R54 Leases - Additional Information (Detail) HTML 60K
70: R55 Summary of Lease Costs Recognized Under Topic 842 HTML 40K
and Other Information Pertaining to Operating
Leases (Detail)
71: R56 Summary of Future Minimum Lease Payments Under HTML 51K
Non-Cancelable Operating Leases Recognized Under
Topic 842 (Detail)
72: R57 Summary of Future Minimum Lease Payments Under HTML 44K
Non-Cancelable Operating Leases (Detail)
73: R58 Basic and Diluted Net Loss Per Share (Detail) HTML 42K
74: R59 Basic and Diluted Net Loss Per Share HTML 26K
(Parenthetical) (Detail)
75: R60 Commitments and Contingencies - Additional HTML 46K
Information (Detail)
76: R61 Summary of Aggregate Non-Cancelable Contractual HTML 38K
Obligations Arising from Manufacturing Obligations
(Detail)
78: XML IDEA XML File -- Filing Summary XML 141K
15: XML XBRL Instance -- srpt-10q_20190630_htm XML 2.64M
77: EXCEL IDEA Workbook of Financial Reports XLSX 69K
11: EX-101.CAL XBRL Calculations -- srpt-20190630_cal XML 228K
12: EX-101.DEF XBRL Definitions -- srpt-20190630_def XML 396K
13: EX-101.LAB XBRL Labels -- srpt-20190630_lab XML 1.08M
14: EX-101.PRE XBRL Presentations -- srpt-20190630_pre XML 767K
10: EX-101.SCH XBRL Schema -- srpt-20190630 XSD 173K
79: JSON XBRL Instance as JSON Data -- MetaLinks 299± 488K
80: ZIP XBRL Zipped Folder -- 0001564590-19-030035-xbrl Zip 263K
EXHIBIT 10.2
Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan
Schedule – Japan Sub-Plan
This Schedule applies to any Awards that are made to directors, employees or other service providers, including but not limited to consultants, of Sarepta Therapeutics K.K. (“Japan Participants”) under the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (the “2018 Plan”).
The 2018 Plan, as amended by the provisions of this Schedule, so as to comply with the provisions of Japanese law, shall be referred to as the “Japan Sub-Plan”. This Schedule shall be construed and operated with that intention. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the 2018 Plan. In the event of any conflict between the 2018 Plan and the Japan Sub-Plan, the provisions of the Japan Sub-Plan shall prevail.
|
1. |
Definition of “Company” |
For the avoidance of doubt and notwithstanding any other provision of the 2018 Plan, the definition of the “Company” includes Sarepta Therapeutics K.K.
|
2. |
Awards to be offered to Japan Participants |
Within the definition of an Award under the 2018 Plan, only Options and Restricted Stock Units (“RSUs”) will be offered to Japan Participants.
|
3. |
Options |
The Options will be subject to the terms and conditions, including but not limited to vesting, under the 2018 Plan and Sarepta’s form of Stock Option Award Agreement under the 2018 Plan.
|
4. |
RSUs |
The RSUs will be subject to the terms and conditions under the 2018 Plan and Sarepta’s form of Restricted Stock Unit Award Agreement under the 2018 Plan.
Without derogating from Section 16(b) of the 2018 Plan, upon settlement in respect of any vested RSUs, a Japan Participant will be deemed to agree, acknowledge and authorize Sarepta to sell a sufficient number of shares otherwise deliverable to such Japan Participant through such means as it may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to be withheld to satisfy all of Sarepta’s (or any subsidiary’s) tax withholding obligations under federal, state, local, foreign or provincial law, not to exceed the Japan Participant’s estimated minimum federal, state and local tax obligations attributable to the RSUs, unless and until the Japan Participant remits to Sarepta (or, if applicable, any subsidiary) an amount in cash or by check sufficient to cover any such tax withholding obligations of Sarepta (or, if applicable, any subsidiary), or the Japan Participant has made other arrangements satisfactory to Sarepta. Nothing herein may be construed as relieving any Japan Participant of any liability for satisfying his or her tax obligations and he or she agrees and acknowledges that the ultimate liability for all taxes related to the RSUs and his or her participation in the 2018 Plan is and remains the sole responsibility of the Japan Participant and that his or her actual tax obligations may exceed the amount, if any, withheld by Sarepta or its subsidiaries.
EXHIBIT 10.2
The Awards are in no respect part of a Japan Participant’s wages, salary or bonus (“Employee Compensation”), but are rather incentive awards, above and beyond his or her Employee Compensation and are granted at the total discretion of the Company.
|
6. |
Shares Not Registered in Japan |
None of the Options or Restricted Stock Units are listed on any stock exchange in Japan, nor registered with any securities exchange in Japan. There was no requirement in the past to file any securities registration statement in Japan.
|
7. |
Payments for Awards |
All payments made by a Japan Participant for or in relation to the Awards are pre-payments for the Awards, and not savings. No deductions shall be made from Employee Compensation in order to pay for any of the Awards.
|
8. |
Restrictions on Transfers |
Notwithstanding Section 14 of the 2018 Plan, Options may not be sold, pledged, assigned, hypothecated, transferred, or disposed in any manner unless all (but not part) of the Options are transferred to a single person or a single legal entity under a single transfer by will or by the laws of descent or distribution.
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 Sarepta Therapeutics, Inc. 10-K 12/31/23 119:18M Donnelley … Solutions/FA 8/02/23 Sarepta Therapeutics, Inc. S-8 8/02/23 4:69K Donnelley … Solutions/FA 2/28/23 Sarepta Therapeutics, Inc. 10-K 12/31/22 119:23M Donnelley … Solutions/FA 3/01/22 Sarepta Therapeutics, Inc. 10-K 12/31/21 121:20M Donnelley … Solutions/FA 3/01/21 Sarepta Therapeutics, Inc. 10-K 12/31/20 124:22M ActiveDisclosure/FA |